Introduction and overview of intravesical therapy for superifcial bladder cancer

M. S. Soloway

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The initial and subsequent management of patients with transitional cell carcinoma of the urinary bladder requires the cooperative effort of the urologist, pathologist, and cytologist. The initial endoscopic session should provide sufficient material to assess accurately the extent of tumor. The tumor is termed superficial if it is confined to the mucosa (Stage Ta and CIS) or lamina propria (T1). Based on the prognostic factors, the clinician decides whether or not intravesical therapy should be incorporated into the treatment plan that is designed to eradicate any remaining postresection tumor(s) as well as retard the development of subsequent tumors. The clinician who chooses to utilize intravesical therapy should be knowledgeable regarding the frequently used drugs: thiotepa, mitomycin C, doxorubicin, and bacillus Calmette-Cuerin (BCG). Each has established efficacy in the treatment and prophylaxis of transitional cell carcinoma. Each also has a different spectrum and incidence of local and systemic toxicity.

Original languageEnglish
Pages (from-to)5-16
Number of pages12
JournalUrology
Volume31
Issue numberSUPPL.
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Transitional Cell Carcinoma
Neoplasms
Mucous Membrane
Thiotepa
Mitomycin
Therapeutics
Mycobacterium bovis
Doxorubicin
Bacillus
Urinary Bladder
Incidence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Urology

Cite this

Introduction and overview of intravesical therapy for superifcial bladder cancer. / Soloway, M. S.

In: Urology, Vol. 31, No. SUPPL., 01.01.1988, p. 5-16.

Research output: Contribution to journalArticle

Soloway, M. S. / Introduction and overview of intravesical therapy for superifcial bladder cancer. In: Urology. 1988 ; Vol. 31, No. SUPPL. pp. 5-16.
@article{4b1db1f6402a499e83d40b78d3a393f7,
title = "Introduction and overview of intravesical therapy for superifcial bladder cancer",
abstract = "The initial and subsequent management of patients with transitional cell carcinoma of the urinary bladder requires the cooperative effort of the urologist, pathologist, and cytologist. The initial endoscopic session should provide sufficient material to assess accurately the extent of tumor. The tumor is termed superficial if it is confined to the mucosa (Stage Ta and CIS) or lamina propria (T1). Based on the prognostic factors, the clinician decides whether or not intravesical therapy should be incorporated into the treatment plan that is designed to eradicate any remaining postresection tumor(s) as well as retard the development of subsequent tumors. The clinician who chooses to utilize intravesical therapy should be knowledgeable regarding the frequently used drugs: thiotepa, mitomycin C, doxorubicin, and bacillus Calmette-Cuerin (BCG). Each has established efficacy in the treatment and prophylaxis of transitional cell carcinoma. Each also has a different spectrum and incidence of local and systemic toxicity.",
author = "Soloway, {M. S.}",
year = "1988",
month = "1",
day = "1",
language = "English",
volume = "31",
pages = "5--16",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "SUPPL.",

}

TY - JOUR

T1 - Introduction and overview of intravesical therapy for superifcial bladder cancer

AU - Soloway, M. S.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - The initial and subsequent management of patients with transitional cell carcinoma of the urinary bladder requires the cooperative effort of the urologist, pathologist, and cytologist. The initial endoscopic session should provide sufficient material to assess accurately the extent of tumor. The tumor is termed superficial if it is confined to the mucosa (Stage Ta and CIS) or lamina propria (T1). Based on the prognostic factors, the clinician decides whether or not intravesical therapy should be incorporated into the treatment plan that is designed to eradicate any remaining postresection tumor(s) as well as retard the development of subsequent tumors. The clinician who chooses to utilize intravesical therapy should be knowledgeable regarding the frequently used drugs: thiotepa, mitomycin C, doxorubicin, and bacillus Calmette-Cuerin (BCG). Each has established efficacy in the treatment and prophylaxis of transitional cell carcinoma. Each also has a different spectrum and incidence of local and systemic toxicity.

AB - The initial and subsequent management of patients with transitional cell carcinoma of the urinary bladder requires the cooperative effort of the urologist, pathologist, and cytologist. The initial endoscopic session should provide sufficient material to assess accurately the extent of tumor. The tumor is termed superficial if it is confined to the mucosa (Stage Ta and CIS) or lamina propria (T1). Based on the prognostic factors, the clinician decides whether or not intravesical therapy should be incorporated into the treatment plan that is designed to eradicate any remaining postresection tumor(s) as well as retard the development of subsequent tumors. The clinician who chooses to utilize intravesical therapy should be knowledgeable regarding the frequently used drugs: thiotepa, mitomycin C, doxorubicin, and bacillus Calmette-Cuerin (BCG). Each has established efficacy in the treatment and prophylaxis of transitional cell carcinoma. Each also has a different spectrum and incidence of local and systemic toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0023845571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023845571&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 5

EP - 16

JO - Urology

JF - Urology

SN - 0090-4295

IS - SUPPL.

ER -